Details of the Drug Combination

General Information of Drug Combination (ID: DC8Z2DS)

Drug Combination Name
Escitalopram Saredutant
Indication
Disease Entry Status REF
Major Depressive Disorder Phase 1 [1]
Component Drugs Escitalopram   DMFK9HG Saredutant   DMSRJY3
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Escitalopram
Disease Entry ICD 11 Status REF
Major depressive disorder 6A70.3 Approved [2]
Escitalopram Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Serotonin transporter (SERT) TT3ROYC SC6A4_HUMAN Inhibitor [4]
------------------------------------------------------------------------------------
Escitalopram Interacts with 3 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [5]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [6]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Metabolism [7]
------------------------------------------------------------------------------------
Escitalopram Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Sodium-dependent serotonin transporter (SLC6A4) OT6FGDLW SC6A4_HUMAN Increases ADR [8]
------------------------------------------------------------------------------------
Indication(s) of Saredutant
Disease Entry ICD 11 Status REF
Anxiety disorder 6B00-6B0Z Discontinued in Phase 3 [3]
Depression 6A70-6A7Z Discontinued in Phase 3 [3]
Saredutant Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Substance-K receptor (TACR2) TTYO0A3 NK2R_HUMAN Antagonist [9]
------------------------------------------------------------------------------------
Saredutant Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Substance-K receptor (TACR2) OTTQHQZM NK2R_HUMAN Affects Binding [10]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT00531622) An Eight-week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2111).
4 Antidepressants and sleep: a review. Perspect Psychiatr Care. 2009 Jul;45(3):191-7.
5 PharmGKB summary: citalopram pharmacokinetics pathway. Pharmacogenet Genomics. 2011 Nov;21(11):769-72.
6 CYP2D6 P34S Polymorphism and Outcomes of Escitalopram Treatment in Koreans with Major Depression. Psychiatry Investig. 2013 Sep;10(3):286-93.
7 Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder. Pharmacogenet Genomics. 2015 Nov;25(11):548-54.
8 Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression. Eur Neuropsychopharmacol. 2009 Jun;19(6):451-6. doi: 10.1016/j.euroneuro.2009.01.010. Epub 2009 Mar 9.
9 Characterization of species-related differences in the pharmacology of tachykinin NK receptors 1, 2 and 3. Biochem Pharmacol. 2009 May 1;77(9):1522-30.
10 Pharmacology of an original and selective nonpeptide antagonist ligand for the human tachykinin NK2 receptor. Eur J Pharmacol. 2005 Jun 1;516(2):104-11.